Destiny 2 Trials of Osiris Population
Bungie

Trials of Osiris, a PvP mode, was one of the main selling points for Season of the Worthy. Season 10 is now out for three weeks and Trials kicking in every weekend in Destiny 2. Each weekend, players get new rewards in Trials by winning a set of matches (3 wins, 5 wins, 7 wins, and flawless). This week, we’ve got a sniper rifle, a rocket launcher, and some armor pieces. Check out our compiled list of this week’s Trials of Osiris inventory in Destiny 2.

Destiny 2 Trials of Osiris Population
Charlemagne Bot

Let’s Talk Numbers…

Well, to put it in perspective, only 12% of Destiny 2’s total population across every platform participated in Trials this weekend (March 27th), according to the Charlemagne bot.

destiny-2-trials-of-osiris
Charlemagne Bot

Now, let’s talk numbers. The overall Destiny 2’s population tracked by Charlemagne on March 27th was 1.46M, across all platforms (PS4, XBO, PC, and Stadia). If we calculate the 12% of that, it comes down to 175,000 players who played Trials on March 27, 2020, which is very low considering in Destiny 1, millions of players tuned in to Trials every weekend. (at peak)

Is Trials of Osiris Dying Already?

Judging from the numbers, yes it is! But, Bungie can fix this problem fairly easily, by adding more incentives for the casual player to play Trials of Osiris. In the end, Destiny 2 is a looter-shooter game. So, all of us are looking for weapons and armor pieces to get. In Destiny 1, players would get the adept version of Trials’ weapons for going Flawless which gave them the elemental burns that were SO useful inside PvE.

Also Read: Destiny 2: Top 5 Weapons For PvP In Season Of The Worthy

In Destiny 2’s Trials of Osiris, we didn’t get any Adept weapons for going flawless. This was the main purpose for PvE players to play Trials back in D1. If this is not fixed soon, Trials would soon become a sweatfest for the top-tier PvP players who are streamers, content creators, and players going to the world’s first on the leaderboards.

Join the conversation